These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24579813)

  • 1. Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.
    Lai CC; Lee KY; Lin SW; Chen YH; Kuo HY; Hung CC; Hsueh PR
    Expert Rev Anti Infect Ther; 2014 Apr; 12(4):401-17. PubMed ID: 24579813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role of nemonoxacin for treatment of common infections.
    Huang CH; Lai CC; Chen YH; Hsueh PR
    Expert Opin Pharmacother; 2015 Feb; 16(2):263-70. PubMed ID: 25529577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of nemonoxacin with special focus on clinical development.
    Qin X; Huang H
    Drug Des Devel Ther; 2014; 8():765-74. PubMed ID: 25045247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK; Triller DM; Yong CS; Lodise TP
    Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G; Rossi V; Salvatori E; Mirelis B
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
    Lauderdale TL; Shiau YR; Lai JF; Chen HC; King CH
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1338-42. PubMed ID: 20065058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia.
    Cheng SL; Wu RG; Chuang YC; Perng WC; Tsao SM; Chang YT; Chang LW; Hsu MC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):743-751. PubMed ID: 30616912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
    Yuan J; Mo B; Ma Z; Lv Y; Cheng SL; Yang Y; Tong Z; Wu R; Sun S; Cao Z; Wu J; Zhu D; Chang L; Zhang Y;
    J Microbiol Immunol Infect; 2019 Feb; 52(1):35-44. PubMed ID: 30181096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
    Liu Y; Zhang Y; Wu J; Zhu D; Sun S; Zhao L; Wang X; Liu H; Ren Z; Wang C; Xiu Q; Xiao Z; Cao Z; Cui S; Yang H; Liang Y; Chen P; Lv Y; Hu C; Lv X; Liu S; Kuang J; Li J; Wang D; Chang L
    J Microbiol Immunol Infect; 2017 Dec; 50(6):811-820. PubMed ID: 26748734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
    Vergis EN; Yu VL
    Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
    Garrison MW; Kawamura NM; Wen MM
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
    Lin L; Chang LW; Tsai CY; Hsu CH; Chung DT; Aronstein WS; Ajayi F; Kuzmak B; Lyon RA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):405-10. PubMed ID: 19884368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in antibiotic therapy for community-acquired pneumonia.
    Viasus D; Garcia-Vidal C; Carratalà J
    Curr Opin Pulm Med; 2013 May; 19(3):209-15. PubMed ID: 23422416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia.
    Jean SS; Chang LW; Hsueh PR
    J Glob Antimicrob Resist; 2020 Dec; 23():388-393. PubMed ID: 33207229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftaroline fosamil: drug profile and clinical data.
    Kanafani ZA
    Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
    Carratalá J; Martín-Herrero JE; Mykietiuk A; García-Rey C
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.
    Van Bambeke F
    Ann Med; 2014 Nov; 46(7):512-29. PubMed ID: 25058176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.